Pulmonary Tuberculosis: Developing Drugs for Treatment

14 December 2022 – the FDA published draft guidance on developing drugs for treatment of pulmonary tuberculosis. Submit Comments by 13 February 2023.

The purpose of this guidance is to assist sponsors in the clinical development of investigational drugs for the treatment of pulmonary tuberculosis (TB). This guidance does not address the development of drugs for latent TB infection or for extrapulmonary TB.

Read more online 
Copyright Widler & Schiemann AG 2022. All Rights Reserved. /